Cardiff Lexington CORP

Cardiff Lexington Corporation has entered into a material definitive agreement for a common stock purchase with an institutional investor, establishing a potential equity line of up to $75 million.

Cardiff Lexington Corporation has amended its Series N Senior Convertible Preferred Stock to remove redemption provisions, effective January 29, 2026.

Cardiff Lexington Corporation announced the resignation of Daniel Thompson from its Board and as Chairman, with CEO Alex Cunningham appointed as the new Chairman.

Cardiff Lexington Corporation announced that its previously issued financial statements for multiple periods should no longer be relied upon due to classification errors in cash flow statements.

Cardiff Lexington Corporation has amended the terms of several series of its preferred stock to include adjustments for stock splits and combinations, and increased the authorized shares of its Series Y Senior Convertible Preferred Stock.

Cardiff Lexington Corporation will restate its financial statements for the first two quarters of 2024 due to misclassification of credit loss expenses.

Cardiff Lexington Corporation reported a net loss of $3.09 million for the first quarter of 2026, a significant increase from the prior year's loss, driven by higher interest expenses and derivative liability losses.

Cardiff Lexington Corporation reported significant revenue growth and a reduced net loss for Q3 2025, driven by its healthcare segment, despite ongoing liquidity concerns and an increased accumulated deficit.

Cardiff Lexington Corporation reported a significant increase in revenue for Q2 2025, but also a substantial rise in net loss driven by soaring interest expenses and ongoing liquidity challenges.

Cardiff Lexington Corporation filed an amended quarterly report revealing a wider net loss for Q1 2025 despite revenue growth, driven by increased operating expenses and interest costs.

Cardiff Lexington Corporation reported a significant decline in revenue and a swing to net loss for the nine months ended September 30, 2024, raising substantial doubt about its ability to continue as a going concern.

Cardiff Lexington Corporation files an amended Q2 2024 report, restating financials due to reclassification of non-cash interest expense and a significant reduction in healthcare revenue from accelerated settlements.

Cardiff Lexington Corporation reported a significant net loss and negative operating cash flow for 2024, raising substantial doubt about its ability to continue as a going concern, despite securing an increased line of credit.

Cardiff Lexington Corporation's 2024 10-K filing highlights a strategic focus on healthcare acquisitions amidst financial challenges, including operating losses and a going concern warning.

Cardiff Lexington Corporation files an amendment to its 2023 annual report to address SEC comments, highlighting a shift to profitability and growth in its healthcare segment.

Cardiff Lexington Corporation has filed an amendment to its 2023 annual report to include the correct independent auditor's report and exhibit.

Cardiff Lexington Corporation files an amendment to its 2023 annual report to address SEC comments, with no other changes to the original filing.

Cardiff Lexington Corporation files a certificate of correction for Series B, C, E, F-1, I, and L preferred stock and reports a net income of $3.03 million for 2023, a significant turnaround from a net loss in 2022.

Cardiff Lexington Corp. Director Louis Jack Staley Sr. was granted 5,000 shares of common stock under the company's equity incentive plan.

Cardiff Lexington Corp reports a restricted stock award granted to Director Catherine B. Pennington.

Gillard B. Johnson III, a Director at Cardiff Lexington Corp, received a restricted stock award of 5,000 common shares on April 1, 2026.

Cardiff Lexington Corp's CEO, Alex H. Cunningham, converted $2.36 million in deferred compensation into 556,528 shares of common stock.

Cardiff Lexington's Chief Financial Officer, Matthew T. Shafer, was granted 62,500 shares of common stock under the company's 2024 Equity Incentive Plan.

Daniel Thompson, Chairman and 10% owner of Cardiff Lexington Corp, reported significant conversions of preferred stock into common stock, increasing his direct beneficial ownership.

Cardiff Lexington Corporation announces stockholder approval for a discretionary reverse stock split ranging from 1-for-2 to 1-for-6 to boost share price and marketability.

Cardiff Lexington Corporation's stockholders approved an amendment to reduce the company's authorized common and preferred stock shares after a recent reverse stock split.

Cardiff Lexington Corporation has entered into a common stock purchase agreement with Leonite Fund I, LP to sell up to $75 million in common stock.

Cardiff Lexington Corporation filed an S-1/A, detailing a proposed 1.2 million share common stock offering contingent on a Nasdaq uplisting, alongside recent financial losses and ongoing liquidity concerns.

Cardiff Lexington Corporation filed an Amendment No. 2 to its S-1 Registration Statement, detailing the terms for a public offering of common stock and representative warrants.

Cardiff Lexington Corporation is offering 1.5 million shares of common stock at an assumed price of $4.00 per share, contingent on its uplisting to The Nasdaq Capital Market, despite ongoing financial challenges including recurring net losses and a going concern doubt.

Cardiff Lexington Corporation files an S-1 registration statement for a common stock offering, contingent on a Nasdaq Capital Market uplisting, amidst recurring operating losses and an extended accounts receivable cycle.

Cardiff Lexington Corporation files Amendment No. 6 to its Form S-1/A registration statement, primarily to include updated exhibits related to its proposed offering of common stock and related securities.